KNTE实时信号 | 通过Getagraph.com最大化利润

购买 114738 min ago

@ $2.26

发出时间: 12 Feb 2024 @ 22:31

回报率: 17.26%

上一信号: Feb 10 - 01:11

上一信号: 出售

回报率: -2.59 %

Live Chart Being Loaded With Signals

Commentary (3 Apr 2024 @ 04:00):

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States...

Stats
今日成交量	2.12M
平均成交量	417 575
市值	124.99M
EPS	$-0.362 ( 2024-04-03 )
下一个收益日期	( $-0.360 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.950
ATR14	$0.00300 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-03	Tananbaum James B.	Sell	520 711	Common Stock
2024-04-03	Tananbaum James B.	Sell	40 501	Stock Option (right to buy)
2024-04-03	Tananbaum James B.	Sell	20 250	Stock Option (right to buy)
2024-04-03	Farzan Nima	Sell	2 186	Common Stock
2024-04-03	Farzan Nima	Sell	1 281 642	Stock Option (right to buy)

INSIDER POWER
-21.61
Last 99 transactions
Buy: 9 508 542 \| Sell: 7 832 534

音量相关性

長: 0.00 (neutral)

短: -0.05 (neutral)

Signal:(69.591) Neutral

Kinnate Biopharma Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Kinnate Biopharma Inc. 相关性 - 货币/商品

0.17
( neutral )

0.15
( neutral )

0.00
( neutral )

0.28
( neutral )

Kinnate Biopharma Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$-799 000 (0.00 %)
EPS:	$-2.42

FY	2023
营收:	$0
毛利润:	$-799 000 (0.00 %)
EPS:	$-2.42

FY	2022
营收:	$0
毛利润:	$-604 000 (0.00 %)
EPS:	$-2.59

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-8.31

Financial Reports:

No articles found.

Kinnate Biopharma Inc.

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.